Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DYADIC INTERNATIONAL, INC.

(DYAI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
5.62(c) 5.67(c) 5.73(c) 5.9(c) 5.6201 Last
189 152 185 037 161 721 147 398 77 513 Volume
-2.26% +0.89% +1.06% +2.97% -4.74% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,00 M - -
Net income 2021 -11,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,7x
Yield 2021 -
Sales 2022 3,30 M - -
Net income 2022 -8,70 M - -
Net Debt 2022 - - -
P/E ratio 2022 -20,3x
Yield 2022 -
Capitalization 166 M 166 M -
Capi. / Sales 2021 55,2x
Capi. / Sales 2022 50,2x
Nbr of Employees 6
Free-Float 49,2%
More Financials
Company
Dyadic International, Inc. is a global biotechnology company. The Company is focused on developing and licensing the C1 platform for use in human and animal pharmaceutical applications across the world. The Company has developed a method for producing commercial quantities of enzymes and other proteins, which it uses to develop and produce some of its own industrial enzymes, as well as licensing this technology to... 
More about the company
Ratings of Dyadic International, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about DYADIC INTERNATIONAL, INC.
09/20DYADIC INTERNATIONAL, INC.(NASDAQCM : DYAI) dropped from S&P Global BMI Index
CI
09/16DYADIC INTERNATIONAL : BPI East September 2021
PU
09/11DYADIC INTERNATIONAL : H.C. Wainwright 23rd Annual Global Investment Conference
PU
09/10DYADIC INTERNATIONAL : to Present at H.C. Wainwright 23rd Annual Global Investment Confere..
AQ
08/19SORRENTO THERAPEUTICS : vaccine shows promise against coronavirus, variants in animal stud..
RE
08/19SORRENTO THERAPEUTICS : Dyadic COVID-19 Vaccine Candidate Elicits "Strong" Immune Response..
MT
08/17DYADIC INTERNATIONAL : Insider Sale Slows Buying Trend of Last Quarter at Dyadic Internati..
MT
08/16INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Dyadic International
MT
08/12DYADIC INTERNATIONAL : Reports Second Quarter 2021 Financial Results and Highlights Recent..
PU
08/12DYADIC INTERNATIONAL : Reports Second Quarter 2021 Financial Results and Highlights Recent..
PU
08/12DYADIC INTERNATIONAL : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/12DYADIC INTERNATIONAL INC : Results of Operations and Financial Condition, Financial Statem..
AQ
08/12Dyadic International, Inc. Reports Earnings Results for the Second Quarter Ended June 3..
CI
08/12SORRENTO THERAPEUTICS : and Dyadic Announce Binding Term Sheet to License Dyadic's Lead CO..
AQ
08/11Top Midday Gainers
MT
More news
News in other languages on DYADIC INTERNATIONAL, INC.
08/17La vente d'initiés ralentit la tendance à l'achat du dernier trimestre chez Dyadic Inte..
04/26Dyadic International veranstaltet Kamingespräch mit dem Titel „The Potential of t..
03/24Dyadic et Medytox vont développer des vaccins contre les variants de la COVID-19
More news
Chart DYADIC INTERNATIONAL, INC.
Duration : Period :
Dyadic International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYADIC INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 5,90 $
Average target price 10,00 $
Spread / Average Target 69,5%
EPS Revisions
Managers and Directors
Mark A. Emalfarb President, Chief Executive Officer & Director
Ping W. Rawson Chief Financial Officer
Michael P. Tarnok Chairman
Ronen Tchelet Vice President-Research & Business Development
Seth J. Herbst Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DYADIC INTERNATIONAL, INC.6.51%166
MODERNA, INC.291.35%165 027
LONZA GROUP AG26.86%57 923
IQVIA HOLDINGS INC.38.49%47 547
CELLTRION, INC.-25.49%31 003
SEAGEN INC.-7.21%29 566